ECSP088430A - Diarilurea para el tratamiento de hipertensión pulmonar - Google Patents

Diarilurea para el tratamiento de hipertensión pulmonar

Info

Publication number
ECSP088430A
ECSP088430A EC2008008430A ECSP088430A ECSP088430A EC SP088430 A ECSP088430 A EC SP088430A EC 2008008430 A EC2008008430 A EC 2008008430A EC SP088430 A ECSP088430 A EC SP088430A EC SP088430 A ECSP088430 A EC SP088430A
Authority
EC
Ecuador
Prior art keywords
treatment
pulmonary hypertension
diarilure
methylamide
fluorophenoxy
Prior art date
Application number
EC2008008430A
Other languages
English (en)
Spanish (es)
Inventor
Bernd Riedl
Joachim Huetter
Peter Sandner
Hanna Tinel
Martina Klein
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of ECSP088430A publication Critical patent/ECSP088430A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EC2008008430A 2005-11-10 2008-05-07 Diarilurea para el tratamiento de hipertensión pulmonar ECSP088430A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05024509 2005-11-10
EP05027450 2005-12-15
EP06012234 2006-06-14

Publications (1)

Publication Number Publication Date
ECSP088430A true ECSP088430A (es) 2008-07-30

Family

ID=37622057

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008430A ECSP088430A (es) 2005-11-10 2008-05-07 Diarilurea para el tratamiento de hipertensión pulmonar

Country Status (18)

Country Link
US (1) US20100035888A1 (enExample)
EP (1) EP1948170A1 (enExample)
JP (1) JP5084736B2 (enExample)
KR (1) KR20080067000A (enExample)
AR (1) AR057849A1 (enExample)
AU (1) AU2006312714A1 (enExample)
BR (1) BRPI0618522A2 (enExample)
CA (1) CA2628849A1 (enExample)
CR (1) CR9953A (enExample)
EC (1) ECSP088430A (enExample)
GT (1) GT200800058A (enExample)
IL (1) IL191178A0 (enExample)
NO (1) NO20082498L (enExample)
PE (1) PE20070806A1 (enExample)
SV (1) SV2009002900A (enExample)
TW (1) TW200733961A (enExample)
UY (1) UY29903A1 (enExample)
WO (1) WO2007054216A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2384160T3 (es) * 1999-01-13 2012-07-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
NZ562414A (en) * 2003-02-21 2009-02-28 Resmed Ltd Headgear assembly for nasal pillow mask
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
DK1626714T3 (da) * 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
BRPI0515946A (pt) * 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP2129376B1 (en) * 2007-01-19 2013-07-24 Bayer HealthCare LLC Treatment of cancers with acquired resistance to KIT inhibitors
US20110178137A1 (en) * 2008-06-25 2011-07-21 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
CN103079567A (zh) * 2010-04-17 2013-05-01 拜尔健康护理有限责任公司 用于疾病和病症的治疗和预防的氟取代的ω-羧基芳基二苯脲的合成代谢产物
CA2813069A1 (en) 2010-10-01 2012-04-05 Bayer Intellectual Property Gmbh Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
EP2686429A4 (en) * 2011-03-14 2014-08-27 Cellworks Res India Private Ltd COMPOSITIONS, PROCESS FOR PREPARING THESE COMPOSITIONS AND METHOD FOR TREATING INFLAMMATORY DISEASES
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478358B1 (en) * 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
DE60319211T2 (de) * 2002-04-10 2009-02-12 The Government Of The United States Of America, As Represented By The Department Of Veterans Affairs Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs
DK1626714T3 (da) * 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
EA010485B1 (ru) * 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
EP1850852A4 (en) * 2005-02-22 2009-11-18 Cedars Sinai Medical Center USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE

Also Published As

Publication number Publication date
PE20070806A1 (es) 2007-09-29
US20100035888A1 (en) 2010-02-11
JP2009514910A (ja) 2009-04-09
CR9953A (es) 2008-10-08
NO20082498L (no) 2008-08-07
AU2006312714A1 (en) 2007-05-18
UY29903A1 (es) 2007-06-29
KR20080067000A (ko) 2008-07-17
AR057849A1 (es) 2007-12-19
EP1948170A1 (en) 2008-07-30
BRPI0618522A2 (pt) 2011-09-06
GT200800058A (es) 2010-02-23
CA2628849A1 (en) 2007-05-18
IL191178A0 (en) 2009-08-03
SV2009002900A (es) 2009-04-28
TW200733961A (en) 2007-09-16
JP5084736B2 (ja) 2012-11-28
WO2007054216A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
ECSP088430A (es) Diarilurea para el tratamiento de hipertensión pulmonar
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
CU20080082A7 (es) Diarilureas para el tratamiento de hipertensión pulmonar
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
NO20083836L (no) N-hydroksyakrylamidforbindelser
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BRPI0807528A2 (pt) Composições lubrificantes pessoais complementares
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
NO20076405L (no) Anvendelse av 24-nor-UDCA
CL2007003189A1 (es) Compuestos derivados de indol y benzofurano; composicion farmaceutica; y uso para el tratamiento o la prevencion de la enfermedad de alzheimer.
MX2022004882A (es) Composicion farmaceutica que comprende selexipag.
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
DOP2007000073A (es) Compuestos para tratar la hipertensión pulmonar
WO2003105751A3 (en) Novel curcumin derivatives
DE602005016803D1 (de) Zusammensetzungen mit strontium und vitamin d und ihre verwendungen
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
WO2010123956A3 (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
BRPI0607003A2 (pt) forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda